Italian pharmaceutical company Menarini IFR stated on Wednesday that the new test launched by A Menarini Diagnostics detects presence of antigens in 12 minutes as well as provides an indication of the viral load that detect the most infectious COVID-19 patients.
The company added that theses tests are different from molecular biology tests because they check for the presence of antigens and therefore potential infection by looking for specific viral proteins. AFIAS Point-of-Care platform can be used in decentralized environments not directly connected to the analysis laboratory, such as emergency rooms, airports and other situations where time or patient comfort matters.
Currently, the company's AFIAS 1 can manage a one-time test and AFIAS 6 allows six samples to be analyzed at the same time. It can be used to perform serological antibody tests to detect the presence and measure the amount of IgM and IgG antibodies in the patient's blood.
In addition, the same AFIAS instrument can be used for serological antibody tests to measure the amount of IgM and IgG antibodies in the patient's blood. The process is the same, with the only variation being the analyzed sample time. The sample is taken by capillary puncture (capillary blood collection) or by venous blood collection, concluded the company.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer